| Literature DB >> 26045718 |
Vorapin Chinchalongporn1, Peter Koppensteiner2, Deborah Prè3, Wipawan Thangnipon4, Leonilda Bilo5, Ottavio Arancio3.
Abstract
In order to understand and find therapeutic strategies for neurological disorders, disease models that recapitulate the connectivity and circuitry of patients' brain are needed. Owing to many limitations of animal disease models, in vitro neuronal models using patient-derived stem cells are currently being developed. However, prior to employing neurons as a model in a dish, they need to be evaluated for their electrophysiological properties, including both passive and active membrane properties, dynamics of neurotransmitter release, and capacity to undergo synaptic plasticity. In this review, we survey recent attempts to study these issues in human induced pluripotent stem cell-derived neurons. Although progress has been made, there are still many hurdles to overcome before human induced pluripotent stem cell-derived neurons can fully recapitulate all of the above physiological properties of adult mature neurons. Moreover, proper integration of neurons into pre-existing circuitry still needs to be achieved. Nevertheless, in vitro neuronal stem cell-derived models hold great promise for clinical application in neurological diseases in the future.Entities:
Year: 2015 PMID: 26045718 PMCID: PMC4456047 DOI: 10.1186/s13195-015-0129-y
Source DB: PubMed Journal: Alzheimers Res Ther Impact factor: 6.982
Summary of methods to analyze neuronal properties
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|
|
| + | – | – | – | + | – | + | – | + | – |
| Intracellular recording on acute brain slices | + | – | – | – | + | + | + | – | + | – |
| Extracellular recording of local field potential | – | – | – | + | – | – | – | – | – | – |
| Multi-electrode array recording | + | + | – | – | – | – | + | – | – | + |
|
| – | – | + | – | – | + | – | + | + | – |
| Calcium imaging | – | + | – | – | + | – | + | – | – | + |
| Optogenetic | + | + | + | + | + | + | + | + | + | + |
| Vesicle cycling | – | – | – | – | + | + | + | – | + | – |
Different aspects are taken into consideration for the methods described (marked + or – depending on the existence of the characteristic described)
Summary of key studies on electrophysiological profiles of human iPSC-derived neurons
|
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|---|
| Method | Human iPSC neuronal differentiation via smad inhibition | Human iPSC-derived NPC neuronal differentiation | Human iPSC-iN cells (via Neurogenin-2 expression) | ||||||
| Cell line | 7889O | WT126, WT33 | Not stated | ||||||
| DIV | 31 to 38 | 41 to 45 | 55 | 55 | 42 | 60 | 42 | 60 | 21 |
| AP firing (% of cells) | 20 | 48 | 60 | 86 | NQ | NQ | NQ | NQ | >95 |
| Single (%) | NQ | NQ | NQ | NQ | NQ | NQ | NQ | NQ | NQ |
| Repetitive (%) | NQ | NQ | NQ | NQ | 16 | 73 | NQ | ||
| Spontaneous AP (%) | NQ | NQ | NQ | NQ | NQ | NQ | NQ | NQ | NQ |
|
| 18 | 27 | 20 | 15 | 25 | NQ | 22 | NQ | 33 to 34 |
| Rin (MΩ) | 2,500.0 | 2,200.0 | 1,700.0 | NQ | NQ | 695.0 | NQ | 302.0 | NQ |
| Cm (pF) | NQ | NQ | NQ | NQ | NQ | 27.0 | NQ | 119.0 | NQ |
| τ (milliseconds) | 34.0 | 29.0 | 21.0 | NQ | NQ | NQ | NQ | NQ | NQ |
| RMP (mV) | −35.0 | −38.0 | −49.0 | NQ | NQ | −44.0 | NQ | −59.0 | NQ |
|
| 89 | 75 | 103 | NQ | NQ | 22 | NQ | 23 | NQ |
| Spontaneous activity (%) | 11 | 16 | 21 | 27 | NQ | NQ | NQ | NQ | >95 |
| Evoked potential (%) | NQ | NQ | NQ | NQ | NQ | NQ | NQ | NQ | >95 |
|
| 8 | 6 | 20 | 15 | NQ | NQ | NQ | NQ | 33 to 34 |
| Co-culture | x | Mouse glial cells | x | x | Mouse astrocytes | Mouse astrocytes | Mouse glial cells | ||
AP, action potential; Cm, membrane capacitance; DIV, days in vitro; iN, induced neuronal; iPSC, induced pluripotent stem cell; NPC, neural progenitor cell; NQ, not quantified; Rin, input resistance; RMP, resting membrane potential; τ, membrane time constant; x, not measured, used or stated
Summary of key studies on electrophysiological profiles of human induced neuronal cells
| Ambasudhan and colleagues, 2011 [ | Caiazzo and colleagues, 2011 [ | Pang and colleagues, 2011 [ | Pfisterer and colleagues, 2011a [ | Pfisterer and colleagues, 2011b [ | Son and colleagues, 2011 [ | Yoo and colleagues, 2011 [ | Koppensteiner and colleagues, 2014 [ | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Method | hiN | hiN | miN | hiN | hiN | hiN | hiN | hiN | hiN | hiN | hiN | hiN | hiN | miN | hiN | hiN | hiN | hiN |
| Age of fibroblast donor | Neonatal | Adult | Embryonic | >40 years | Fetal | Fetal | Neonatal | 11 years | Embryonic | Fetal | Fetal | Embryonic | Adult | Embryonic | Embryonic | Neonatal | 30 years | Adult |
| Number of cell lines | 2 | 2 | 1 | 4 | 3 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 |
| Viral factors | Brn2, Myt1l, miR-124 | Ascl1, Nurr1, Lmx1a | BAM + NeuroD1 | BAM + Lmx1a + FoxA2 | BAM | BAM | BAM + four factors | BAM + five factors | miR-9/9*, miR-124, DAM | BAM + Zic1 | ||||||||
| Conversion efficiency (%) | 4 to 8 | 1.5 to 11 | 2 | 3 to 5 | 2 to 4 | 2 to 4 | 2 to 4 | NQ | 5 | 10 | 13 | 16 | 1 to 4 | NQ | NQ | NQ | NQ | NQ |
| DIV | 25 to 30 | 30 | 16 | 18 | 14 to 25 | 34 to 35 | 28 to 35 | 21 | 30 to 32 | 30 to 32 | 30 to 32 | 30 to 32 | 23 to 34 | NQ | NQ | 35 to 56 | 35 to 56 | 21 to 28 |
| AP firing (% of cells) | 81 | 12 | NQ | NQ | 21 | 100 | 79 | NQ | 86 | 83 | 79 | 91 | 47 | 90 | NQ | 85 | 60 | 63 |
| Single (%) | NQ | NQ | NQ | NQ | NQ | NQ | NQ | NQ | NQ | NQ | NQ | NQ | NQ | NQ | NQ | NQ | NQ | 62 |
| Repetitive (%) | 20 | NQ | NQ | NQ | NQ | NQ | NQ | NQ | NQ | NQ | NQ | NQ | NQ | NQ | NQ | 77 | 56 | 7 |
| Spontaneous AP (%) | 15 | NQ | 81 | NQ | 2 | 0 | 3.0 | NQ | 29 | 0 | NQ | NQ | NQ | NQ | NQ | 10 | NQ | 0 |
|
| 29 | 25 | 16 | 8 | 42 | 5 | 29 | NQ | 7 | 6 | 14 | 12 | 60 | 10 | NQ | 27 | 15 | 27 |
| Rin (MΩ) | 405.0 | 1,067.0 | 1,100.0 | NQ | 1,770.0 | 1,110.0 | 1,500.0 | x | 157.0 | 152.0 | 966.0 | 843.0 | x | NQ | NQ | 2,600.0 | 2,800.0 | 1,060.0 |
| Cm (pF) | 30.5 | 35.9 | 10.6 | NQ | 16.0 | 25.1 | 23.0 | x | NQ | NQ | NQ | NQ | x | NQ | NQ | 16.3 | 22.9 | 33.3 |
| τ (milliseconds) | NQ | NQ | NQ | NQ | NQ | NQ | NQ | x | NQ | NQ | NQ | NQ | x | NQ | NQ | NQ | NQ | 35.4 |
| RMP (mV) | −45.0 | x | −41.8 | NQ | −52.1 | −59.5 | −41.0 | x | −45.3 | −41.6 | −62.4 | −58.6 | x | −49.5 | NQ | −42.0 | −31.4 | −42.1 |
|
| 21 | 21 | 16 | 8 | 52 | 21 | 29 | x | 7 | 6 | 14 | 12 | x | 6 | NQ | 27 | 15 | 27 |
| Spontaneous activity (%) | 25 | 43 | x | x | 0 | 19 | 33 | x | x | x | x | x | x | x | x | 71 | 84 | 0 |
| Evoked potential (%) | x | x | x | x | 0 | 14 | 0 | x | x | x | x | x | x | x | x | 45 | 47 | 0 |
|
| 8 | 7 | x | x | 20 | 21 | 6 | x | x | x | x | x | x | x | x | 12 to 14 | 10 to 12 | 9 to 57 |
| Co-culture | x | x | x | x | Mouse cortical neurons | x | x | x | x | x | x | x | x | Mouse glial cells | x | |||
Note the more immature electrophysiological properties of neurons converted from adult somatic cells compared with those converted from fetal or neonatal tissues. AP, action potential; BAM, Brn2, Ascl1, Myt1l; DAM, NeuroD2, Ascl1, Myt1l; Cm, membrane capacitance; DIV, days in vitro; five factors, Lhx3, Hb9, Isl1, Ngn2, NeuroD1; four factors, Lhx3, Hb9, Isl1, Ngn2; hiN, human induced neuronal; miN, mouse induced neuronal; NQ, not quantified; Rin, input resistance; RMP, resting membrane potential; τ, membrane time constant; x, not measured, used or stated
Connectivity and circuitry dysfunction observed in published human iPSC models of neurological diseases
|
|
|
|
|
|---|---|---|---|
| Alzheimer’s disease | Cortical neurons | • Accumulated extracellular Aβ oligomers inside familial and sporadic neurons, leading to oxidative stress | [ |
| • Selectively decreased glutamatergic neurons rather than GABAergic neurons with increasing concentrations of the globulomeric form of Aβ42 | |||
| • Redistributed hyperphosphorylated tau to the somatodendritic compartments | |||
| Amytrophic lateral sclerosis | Motor neurons, astrocytes | • Hyperexcitability of amytrophic lateral sclerosis patient-derived motor neurons | [ |
| • Kv7 channel-activator retigabine could revert motor neuron hyperexcitability | |||
| • Astrocytes from amytrophic lateral sclerosis patient-derived iPSCs show toxicity towards motor neurons in co-culture | |||
| Dravet syndrome | Glutamatergic and GABAergic neurons | • Impaired action potential generation in GABAergic neurons derived from Dravet syndrome patient tissue | [ |
| • Hyperexcitability and spontaneous epileptic action potential firing in glutamatergic neurons | |||
| • Increased sodium currents | |||
| • Hyperexcitability was reduced after treatment with phenytoin | |||
| Down syndrome | Cortical neurons | • Defected the ability to form functional synapses in early trisomy of chromosome 21 iPSC neurons | [ |
| • Diminished number of neural progenitor cells associated with a proliferation deficit and increased apoptosis. | |||
| • Reduced number and length of neurites from soma of neurons | |||
| • Decreased frequencies of spontaneous neurotransmission, affecting excitatory and inhibitory synapses equally | |||
| Fragile X syndrome | NPCs, neurons of unspecified subtype | • Impaired neuronal differentiation of Fragile X syndrome patient-derived iPSCs | [ |
| • No clear effect on glial differentiation | |||
| • No activation of mutant FMR1 locus during iPSC generation from Fragile X syndrome patient tissue | |||
| Parkinson’s disease | Dopaminergic neurons | • Reduced numbers of neurites and neurite arborization | [ |
| • Decreased dopamine uptake and disrupted the precision of dopamine transmission by increasing spontaneous dopamine release | |||
| Schizophrenia | Glutamatergic neurons | • Elevated levels of secreted catecholamines including dopamine, norepinephrine, and epinephrine secretion | [ |
| • Increased percentage of tyrosine hydroxylase-positive neurons, the first enzymatic step for catecholamine biosynthesis | |||
| • Decreased neuronal connectivity and numbers of neurites | |||
| Spinal muscular atrophy | Motor neurons | • Attenuated levels of SMN1 protein in spinal muscular atrophy iPSC neurons, resulting in the selective degeneration of motor neurons | [ |
| • Decreased numbers of motor neuron survival with a reduced size | |||
| • Reduced axonal growth and neuromuscular junction formation | |||
| Rett syndrome | Glutamatergic neurons | • Diminished number of synapses and dendritic spines | [ |
| • Abnormally decreased activity-dependent calcium oscillations | |||
| • Reduced frequencies and amplitude of spontaneous synaptic currents, reflecting fewer release sites or a decreased release probability of neurotransmission | |||
| Phelan–McDermid syndrome | Forebrain neurons | • Impaired excitatory neurotransmission indicated by reduced amplitudes and frequencies of spontaneous excitatory postsynaptic currents | [ |
| • Disrupted the ratio of cellular excitation and inhibition in Phelan–McDermid syndrome neurons |
Aβ, amyloid beta; GABA, γ-aminobutyric acid; iPSC, induced pluripotent stem cell; NPC, neural progenitor cell